Clinical Trial

Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 22, 2025 (before its estimated May 4, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single-arm, open, dose-increasing and dose-expanding phase I clinical trial to investigate the safety, tolerability and cytodynamic characteristics of MC-1-50 cell preparation, and to preliminatively observe the efficacy of MC-1-50 cell preparation in patients with refractory SLE, and to explore the applicable dose regimen for phase II clinical trials.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-18.
Status change: Not Yet Recruiting → Recruiting 2025-12-18
Trial Details
NCT Number NCT06892145
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Collaborators: Second Affiliated Hospital, Zhejiang University, School of Medicine
Conditions Systemic Lupus Erythematosus (SLE), Refractory
Enrollment 12 participants
Start Date 2025-06-12
Primary Completion 2026-05-04 (estimated)
Study Completion 2028-02-16 (estimated)
Updated on ClinicalTrials.gov 2025-12-22